Myvizhi Esai Selvan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Myvizhi Esai Selvan has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Zeynep Hülya Gümüş
Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
27 shared publications - Robert J. Klein
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
24 shared publications - Kenan Onel
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, USA; Department of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, USA
9 shared publications - Alyna Katti
Department of Pediatrics, The University of Chicago, Chicago, Illinois
7 shared publications Andrew D. Skol
7 shared publicationsAnita Ng
7 shared publications
Latest Publications
- Open Access
The genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African (∼35%) and Admixed American genetic ancestry (∼15%) and young adults aged 18-39 years (∼30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis. CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with D NMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78–0.95, p =0.002; validation: OR=0.84, 95% CI = 0.75–0.93, p =0.001). Participants of Admixed American ancestry showed a similar trend. Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15–1.48, p =4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87–0.99, p =0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A - and TET2 -mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2 -mutant CHIP (pooled OR=0.84, 95% CI = 0.70–1.00, p =0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A -mutant CHIP (pooled OR=1.19, 95% CI = 1.00–1.42, p =0.05; pooled OR=1.12, 95% CI = 1.01–1.25, p =0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged ≥40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
Open AccessThe genetic, clinical and immune landscape of clonal hematopoiesis across adulthood in the multi-ancestry Mount Sinai Million cohort
Clonal hematopoiesis of indeterminate potential (CHIP), the age-associated expansion of blood cell clones carrying acquired driver mutations, remains less well characterized in young adults, across genetic ancestries, and in clinical populations. We analyzed whole-exome sequencing and longitudinal electronic health record (EHR) data from 59,598 adults in the Mount Sinai Million Health Discoveries Program, an urban, multi-ancestry hospital-based cohort that includes substantial representation of African (∼35%) and Admixed American genetic ancestry (∼15%) and young adults aged 18-39 years (∼30%). After sample QC, separate analyses were performed in discovery (n = 28,051) and validation (n = 26,938) cohorts defined by sequencing platform and combined by meta-analysis. CHIP was detected in 8.5% of participants in each cohort and in 4.0% of young adults, with D NMT3A, TET2, ASXL1, and PPM1D the most frequently mutated genes. Prevalence and clone size increased with age across ancestry groups. After adjusting for age, participants of African ancestry had lower CHIP prevalence than those of European ancestry in both cohorts (discovery: OR=0.86, 95% CI = 0.78–0.95, p =0.002; validation: OR=0.84, 95% CI = 0.75–0.93, p =0.001). Participants of Admixed American ancestry showed a similar trend. Higher systemic immune-inflammation index (SII) was associated with CHIP after adjusting for age, sex and ancestry in both cohorts (pooled OR=1.30, 95% CI = 1.15–1.48, p =4.78e-5). Heterozygosity at an HLA class II locus HLA-DPA1 was associated with 7% lower odds of overall CHIP (pooled OR=0.93, 95% CI = 0.87–0.99, p =0.03). Driver-stratified analyses revealed distinct HLA class II nominal association patterns for DNMT3A - and TET2 -mutant CHIP. Particularly, HLA-DQB1 heterozygosity associated with lower odds of TET2 -mutant CHIP (pooled OR=0.84, 95% CI = 0.70–1.00, p =0.05), HLA-DQA1 and HLA-DOB heterozygosity associated with higher odds of DNMT3A -mutant CHIP (pooled OR=1.19, 95% CI = 1.00–1.42, p =0.05; pooled OR=1.12, 95% CI = 1.01–1.25, p =0.03 respectively). Longitudinal EHR analyses revealed CHIP associations with several incident diseases that varied by driver gene and clone size. The broadest pattern of associations involved high-risk CHIP genes and encompassed hematologic malignancies, solid tumors, cardiovascular outcomes, hypertension, and COPD. High-VAF clones were the main drivers of these associations. Among adults aged ≥40 years, phenome-wide analyses identified a Bonferroni-significant association with incident myeloproliferative disease and nominal associations with incident pancytopenia, anemia, cardiomegaly, and chronic renal failure. Young-adult CHIP was nominally associated with incident nodular goiter and esophageal disease. These findings characterize CHIP across adulthood and genetic ancestry and reveal inherited immune variation and systemic inflammation as correlates in a hospital-based population.
- Open Access
Inherited genetic risk factors in young-onset lung cancer
Introduction: Lung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. Methods: We performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age BRIP1 , ERCC6 , MSH5), and in cilia-related genes, notably GPR161 . At the pathway level, DDR genes were significantly enriched (OR=1.66, p =0.007), with the strongest signal in the Fanconi Anemia pathway and among females (OR=1.96, p =0.01). Enrichment was also observed in inborn errors of immunity pathways, with strongest signals in antibody deficiency and the complement system genes. Young-onset patients additionally exhibited higher lung cancer PRS. Conclusion: Young-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.
Open AccessInherited genetic risk factors in young-onset lung cancer
Introduction: Lung cancer is rare before age 45, and its inherited genetic basis remains poorly defined. Methods: We performed whole-genome sequencing in 171 predominantly young-onset lung cancer patients and integrated these data with whole-exome sequencing from six major lung cancer consortia, yielding 9,065 patients. After quality control, analyses focused on 6,545 individuals of European ancestry, the largest ancestral group. We compared the prevalence of rare pathogenic and likely pathogenic (P/LP) germline variants between 186 young-onset (age BRIP1 , ERCC6 , MSH5), and in cilia-related genes, notably GPR161 . At the pathway level, DDR genes were significantly enriched (OR=1.66, p =0.007), with the strongest signal in the Fanconi Anemia pathway and among females (OR=1.96, p =0.01). Enrichment was also observed in inborn errors of immunity pathways, with strongest signals in antibody deficiency and the complement system genes. Young-onset patients additionally exhibited higher lung cancer PRS. Conclusion: Young-onset lung cancer exhibits a distinct germline genetic architecture, characterized by enrichment of rare P/LP variants in DDR, cilia-related, and immune pathways, and an elevated lung cancer PRS. These findings support a greater role for inherited susceptibility in early-onset disease and have implications for risk stratification, earlier screening, and precision prevention.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 29 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1873-1877
Distinct Characteristics of Lymphoid and Myeloid Clonal Hematopoiesis in World Trade Center First Responders
- 29 July 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (10) , 1873-1877
Distinct Characteristics of Lymphoid and Myeloid Clonal Hematopoiesis in World Trade Center First Responders
- 6 January 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (8) , 2123-2133
Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD). Methods: We analyzed whole-exome sequencing data from 587 Crohn’s disease (CD), 441 ulcerative colitis (UC), and 293 non-IBD controls to assess CHIP prevalence and used logistic regression to study associations with clinical outcomes. Results: Older UC patients (age > 45) harbored increased myeloid-CHIP mutations compared to younger patients (age ≤ 45) (P = .01). Lymphoid-CHIP was more prevalent in older IBD patients (P = .007). Young CD patients were found to have myeloid-CHIP with high-risk features. Inflammatory bowel disease patients with CHIP exhibited unique mutational profiles compared to controls. Steroid use was associated with increased CHIP (P = .05), while anti-TNF therapy was associated with decreased myeloid-CHIP (P = .03). Pathway enrichment analyses indicated an overlap between CHIP genes, IBD phenotypes, and inflammatory pathways. Conclusions: Our findings underscore a connection between IBD and CHIP pathophysiology. Patients with IBD and CHIP had unique risk profiles, especially among older UC patients and younger CD patients. These findings suggest distinct evolutionary pathways for CHIP in IBD and necessitate awareness among IBD providers and hematologists to identify patients potentially at risk for CHIP-related complications including malignancy, cardiovascular disease, and acceleration of their inflammatory disease.
- 6 January 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (8) , 2123-2133
Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Background: Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD). Methods: We analyzed whole-exome sequencing data from 587 Crohn’s disease (CD), 441 ulcerative colitis (UC), and 293 non-IBD controls to assess CHIP prevalence and used logistic regression to study associations with clinical outcomes. Results: Older UC patients (age > 45) harbored increased myeloid-CHIP mutations compared to younger patients (age ≤ 45) (P = .01). Lymphoid-CHIP was more prevalent in older IBD patients (P = .007). Young CD patients were found to have myeloid-CHIP with high-risk features. Inflammatory bowel disease patients with CHIP exhibited unique mutational profiles compared to controls. Steroid use was associated with increased CHIP (P = .05), while anti-TNF therapy was associated with decreased myeloid-CHIP (P = .03). Pathway enrichment analyses indicated an overlap between CHIP genes, IBD phenotypes, and inflammatory pathways. Conclusions: Our findings underscore a connection between IBD and CHIP pathophysiology. Patients with IBD and CHIP had unique risk profiles, especially among older UC patients and younger CD patients. These findings suggest distinct evolutionary pathways for CHIP in IBD and necessitate awareness among IBD providers and hematologists to identify patients potentially at risk for CHIP-related complications including malignancy, cardiovascular disease, and acceleration of their inflammatory disease.
- Open Access
Clonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD). We analyzed whole exome sequencing data from 587 Crohn’s disease (CD), 441 ulcerative colitis (UC), and 293 non-IBD controls to assess CHIP prevalence and used logistic regression to study associations with clinical outcomes. Older UC patients (age>45) harbored increased myeloid-CHIP mutations compared to younger patients (age≤45) ( p= 0.01). Lymphoid-CHIP was more prevalent in older IBD patients ( p =0.007). Young CD patients were found to have myeloid-CHIP with high-risk features. IBD patients with CHIP exhibited unique mutational profiles compared to controls. Steroid use was associated with increased CHIP ( p= 0.05), while anti-TNF therapy was associated with decreased myeloid-CHIP ( p= 0.03). Pathway enrichment analyses indicated overlap between CHIP genes, IBD phenotypes, and inflammatory pathways. Our findings underscore a connection between IBD and CHIP pathophysiology. Patients with IBD and CHIP had unique risk profiles especially among older UC patients and younger CD patients. These findings suggest distinct evolutionary pathways for CHIP in IBD and necessitate awareness among IBD providers and hematologists to identify patients potentially at risk for CHIP-related complications including malignancy, cardiovascular disease and acceleration of their inflammatory disease.
Open AccessClonal Hematopoiesis of Indeterminate Potential in Crohn’s Disease and Ulcerative Colitis
Clonal hematopoiesis of indeterminate potential (CHIP) is the presence of somatic mutations in myeloid and lymphoid malignancy genes in the blood cells of individuals without a hematologic malignancy. Inflammation is hypothesized to be a key mediator in the progression of CHIP to hematologic malignancy and patients with CHIP have a high prevalence of inflammatory diseases. This study aimed to identify the prevalence and characteristics of CHIP in patients with inflammatory bowel disease (IBD). We analyzed whole exome sequencing data from 587 Crohn’s disease (CD), 441 ulcerative colitis (UC), and 293 non-IBD controls to assess CHIP prevalence and used logistic regression to study associations with clinical outcomes. Older UC patients (age>45) harbored increased myeloid-CHIP mutations compared to younger patients (age≤45) ( p= 0.01). Lymphoid-CHIP was more prevalent in older IBD patients ( p =0.007). Young CD patients were found to have myeloid-CHIP with high-risk features. IBD patients with CHIP exhibited unique mutational profiles compared to controls. Steroid use was associated with increased CHIP ( p= 0.05), while anti-TNF therapy was associated with decreased myeloid-CHIP ( p= 0.03). Pathway enrichment analyses indicated overlap between CHIP genes, IBD phenotypes, and inflammatory pathways. Our findings underscore a connection between IBD and CHIP pathophysiology. Patients with IBD and CHIP had unique risk profiles especially among older UC patients and younger CD patients. These findings suggest distinct evolutionary pathways for CHIP in IBD and necessitate awareness among IBD providers and hematologists to identify patients potentially at risk for CHIP-related complications including malignancy, cardiovascular disease and acceleration of their inflammatory disease.
- Open Access
Distinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders
Clonal hematopoiesis of indeterminate potential (CHIP) represents the presence of clonal somatic mutations in blood cells in otherwise healthy individuals. While CHIP is known to increase risk for hematologic malignancies and cardiovascular disease, its association with airborne carcinogens remains largely unknown. We investigated CHIP mutations in 9/11 World Trade Center (WTC) disaster responders (n=350), who experienced substantial exposure to a complex mix of airborne carcinogens. Ultra-deep whole-exome sequencing at 250X was performed on banked blood samples. We characterized CHIP mutations and their associations with clinical factors (age, ancestry, gender, body mass index, cardiovascular disease, stroke), laboratory parameters (peripheral blood counts), mental and cognitive assessments, exposure data, and HLA zygosity. Statistical methods included Fisher’s exact test, Wilcoxon rank sum test, and multivariate logistic regression. Findings were compared to unexposed controls (n=293) analyzed using identical methods. Among WTC participants, CHIP prevalence was 34.2%, with myeloid-CHIP (M-CHIP) at 16.2% and lymphoid-CHIP (L-CHIP) at 21.4%. M-CHIP prevalence correlated positively with age ( p =0.02), smoking history ( p= 0.01), and lower platelet counts ( p =0.03). The most frequent M-CHIP mutations were in DNMT3A, TET2, PPM1D , while L-CHIP mutations were in EEF1A1, DDX11 and KMT2D . Notably, DDX11 mutations were associated with lower Montreal Cognitive Assessment scores ( p =6.57e-03). Comparison with unexposed controls demonstrated higher CHIP prevalence in WTC responders, particularly in those 55 or younger. Study highlights the potential utility of deep sequencing for CHIP detection with clinical, laboratory and exposure data to develop personalized risk-adapted screening programs for cancer and other CHIP-related conditions in individuals exposed to airborne carcinogens.
Open AccessDistinct characteristics of lymphoid and myeloid clonal hematopoiesis in World Trade Center first responders
Clonal hematopoiesis of indeterminate potential (CHIP) represents the presence of clonal somatic mutations in blood cells in otherwise healthy individuals. While CHIP is known to increase risk for hematologic malignancies and cardiovascular disease, its association with airborne carcinogens remains largely unknown. We investigated CHIP mutations in 9/11 World Trade Center (WTC) disaster responders (n=350), who experienced substantial exposure to a complex mix of airborne carcinogens. Ultra-deep whole-exome sequencing at 250X was performed on banked blood samples. We characterized CHIP mutations and their associations with clinical factors (age, ancestry, gender, body mass index, cardiovascular disease, stroke), laboratory parameters (peripheral blood counts), mental and cognitive assessments, exposure data, and HLA zygosity. Statistical methods included Fisher’s exact test, Wilcoxon rank sum test, and multivariate logistic regression. Findings were compared to unexposed controls (n=293) analyzed using identical methods. Among WTC participants, CHIP prevalence was 34.2%, with myeloid-CHIP (M-CHIP) at 16.2% and lymphoid-CHIP (L-CHIP) at 21.4%. M-CHIP prevalence correlated positively with age ( p =0.02), smoking history ( p= 0.01), and lower platelet counts ( p =0.03). The most frequent M-CHIP mutations were in DNMT3A, TET2, PPM1D , while L-CHIP mutations were in EEF1A1, DDX11 and KMT2D . Notably, DDX11 mutations were associated with lower Montreal Cognitive Assessment scores ( p =6.57e-03). Comparison with unexposed controls demonstrated higher CHIP prevalence in WTC responders, particularly in those 55 or younger. Study highlights the potential utility of deep sequencing for CHIP detection with clinical, laboratory and exposure data to develop personalized risk-adapted screening programs for cancer and other CHIP-related conditions in individuals exposed to airborne carcinogens.
- Open Access
- 23 July 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (34) , 2612
Editorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization
- 23 July 2024
- Published by Springer Nature in Oncogene
- Vol. 43 (34) , 2612
Open AccessEditorial Expression of Concern: Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (86) , eadg0878
Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells
During persistent antigen stimulation, such as in chronic infections and cancer, CD8 T cells differentiate into a hypofunctional programmed death protein 1–positive (PD-1 + ) exhausted state. Exhausted CD8 T cell responses are maintained by precursors (Tpex) that express the transcription factor T cell factor 1 (TCF-1) and high levels of the costimulatory molecule CD28. Here, we demonstrate that sustained CD28 costimulation is required for maintenance of antiviral T cells during chronic infection. Low-level CD28 engagement preserved mitochondrial fitness and self-renewal of Tpex, whereas stronger CD28 signaling enhanced glycolysis and promoted Tpex differentiation into TCF-1 neg exhausted CD8 T cells (Tex). Furthermore, enhanced differentiation by CD28 engagement did not reduce the Tpex pool. Together, these findings demonstrate that continuous CD28 engagement is needed to sustain PD-1 + CD8 T cells and suggest that increasing CD28 signaling promotes Tpex differentiation into more functional effector-like Tex, possibly without compromising long-term responses.
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (86) , eadg0878
Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1 + PD-1 + CD8 T cells
During persistent antigen stimulation, such as in chronic infections and cancer, CD8 T cells differentiate into a hypofunctional programmed death protein 1–positive (PD-1 + ) exhausted state. Exhausted CD8 T cell responses are maintained by precursors (Tpex) that express the transcription factor T cell factor 1 (TCF-1) and high levels of the costimulatory molecule CD28. Here, we demonstrate that sustained CD28 costimulation is required for maintenance of antiviral T cells during chronic infection. Low-level CD28 engagement preserved mitochondrial fitness and self-renewal of Tpex, whereas stronger CD28 signaling enhanced glycolysis and promoted Tpex differentiation into TCF-1 neg exhausted CD8 T cells (Tex). Furthermore, enhanced differentiation by CD28 engagement did not reduce the Tpex pool. Together, these findings demonstrate that continuous CD28 engagement is needed to sustain PD-1 + CD8 T cells and suggest that increasing CD28 signaling promotes Tpex differentiation into more functional effector-like Tex, possibly without compromising long-term responses.